Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation. GenSciP166 was assayed in vitro as well as in vivo in the MC903 atopic dermatitis murine model.